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Biomedical Tissue 
Engineering-Where We Go in 
the Future
Chair: Lynda Bonewald
Interim Vice Chancellor for Research
Goal for Session
• Present Biomedical and Tissue 
Engineering in our area
• Showcase successful collaborations
• Provide ideas for products and applications
• Establish academic/business partnerships
Panelists
• Mark Johnson -Role of Genetics
• Delbert Day -How to be successful as 
an entrepreneur.
• Michael Detamore -Moving 
biomaterials into applications.
• Marco Brotto -Potential therapeutics 
for muscle wasting.
• Daniel Leon–Salas -Biomedical 
devices for bone, muscle, heart.
New Insights Revealed by Genetic Studies 
and the Future of Treating Bone Health 
Related Issues
Mark L. Johnson, Ph.D.
Department of Oral Biology
UMKC School of Dentistry
Genetics of Bone
• 20-70% of the variation in bone properties are 
estimated to be inherited
• During the past 15 years there have been a number 
of major efforts to identify genes underlying bone 
traits
• While it was originally thought (hoped) that a few 
major effect genes would underlie various bone 
traits; current results indicate dozens, perhaps 
hundreds of genes may be involved.
Osteoporosis
The Osteoporosis Epidemic
• 30-40% increase in population over 50 years of age by 
2020
• If nothing changes 50% of population over 50 years will 
have osteoporosis and or low bone mass
– Osteoporotic fractures annually exceed the combined 
numbers of heart attacks, strokes and breast cancer
– ~50% of women who suffer an osteoporotic hip 
fracture will die within 1 year.
• Increase in health care costs predicted to be as high as 
$200 billion
Genetic Dissection of Bone Traits
• Candidate gene studies (CGS)
• Genome wide association studies (GWAS)
• Gene expression profiling (GEP)
Dr. H.-W. Deng
• Single gene trait segregating in families
– Dr. Y. Ueki (SH3BP2, Cherubism)
– Dr. M.L. Johnson (LRP5, HBM)
Genes Identified/Confirmed from 
Genome Studies
Gene Signaling Pathway Study Design
LRP5 Wnt/β-catenin Human family linkage
GWAS, CGS
Mouse genetics
SOST Wnt/β-catenin Human family linkage
GWAS
sFRP4 Wnt/β-catenin GWAS,  CGS
Mouse genomics and genetics
ALOX 12/15 Arachidonic acid 
metabolism
Mouse genomics and genetics
GWAS,  CGS
BMP2 BMP signaling GWAS, CGS
Mouse genomics and genetics
VDR Transcriptional regulation CGS, GWAS
ESR1/ESR2 Transcriptional regulation CGS, GWAS
STAT1 Transcriptional regulation GEP, CGS
Mouse genetics
Col1A1 Extracellular matrix CGS 
GWAS 
GWAS: genome-wide association study; CGS: candidate gene study; GEP: gene expression profiling
Johnson, et al. Genome Med. 2009 Sep 7;1(9):84
Impact of Bone Gene Identifications
• Revealed new pathways important in bone 
biology (ex: Wnt/β-catenin signaling)
• Generated new targets for drug 
development for treating diseases of bone
• Placed us on the threshold of personalized 
bone treatments/therapies
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Sclerosteosis/Van Buchem Diseases
• Sclerosteosis:  mutation in the SOST gene
• Van Buchem:  large deletion of the 
promoter region of the SOST gene
• SOST gene encodes the protein sclerostin
LRP5 and Sclerostin
• LRP5 is a co-receptor (along with frizzled) 
for the Wnt proteins and this binding 
activates Wnt/β-catenin signaling pathway.
• Sclerostin binds LRP5 and prevents Wnt 
proteins from binding, thereby inhibiting the 
Wnt/β-catenin signaling pathway.  
Wnt/β-catenin Signaling Pathway 
as a Drug Target
• Sclerostin antibody (Amgen)
• Diphenylsulfonyl sulfonamides (target sFRPs) 
(developed by Wyeth)
• GSK-3β inhibitors (several groups)
• Sclerostin Inhibitors (OsteoGeneX Inc., KC)
New Biology Revealed by Studying the Role of 
Wnt/β-catenin Signaling in Bone
• Better understanding of how bone responds to mechanical 
loading (exercise) and the role of various bone cells in the 
bone regulation process – Dr. L. Bonewald, Dr. S. Dallas, Dr. 
M.L. Johnson (UMKC)
• Means to identify other factors produced by bone cells that 
regulate bone formation and new assays for monitoring bone 
formation – Dr. J. Gorski (UMKC)
• New targets for therapy – Dr. D Ellies (OsteoGeneX, Inc.)
• New paradigm for treating bone diseases such as 
osteoporosis; i.e. perhaps we can develop agents that will 
enhance the skeleton’s ability to respond to mechanical load 
and thereby use the natural mechanisms intrinsic in bone to 
treat diseases such as osteoporosis
Future of Bone Scaffolds and Bone 
Tissue Engineering
• Creating better scaffolds 
– Ultimately we want to achieve scaffolds that 
are indistinguishable from bone
• Bone tissue engineering
– Growing new bone from an individual’s MSCs 
(personalized therapy).
Future of Bone Scaffolds and Bone 
Tissue Engineering
• These efforts need to incorporate a full 
understanding of basic bone biology; 
including an understanding of the pathways 
that regulate normal bone formation. 
• Genetic studies have revealed a  number of 
important pathways and potential targets for 
treating bone diseases and likewise revealed 
biology needed to support scaffold and bone 
tissue engineering development.
Personalized Therapy for Treating 
Bone Diseases
The identification of genes underlying 
various bone traits and understanding how 
these contribute to both variation in the 
general population and basic bone biology 
will be key steps towards developing 
therapeutic approaches that are customized 
on an individual by individual basis.
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CREATING A HEALTH CARE  BUSINESS 
FROM 
UNIVERSITY RESEARCH
BY
Delbert E. Day
Missouri Life Sciences Summit                         
Panel on Biomedical Tissue Engineering                    
9 March 2010
Missouri University of Science and Technology
&
MO-SCI CORP.
Consortium for Bone and Tissue Repair 
and Regeneration (CBTRR)
Joint MS&T/UMKC center to research and 
develop advanced biomaterials, biosensors, and 
biointerfaces for the repair and regeneration 
of traumatized bone and tissues
Uses of Bioinert, Bioactive & Biocompatible Glasses 
Dental  Implants/Repair
(caps, crowns, veneers)
Destroying Malignant Tumors
(liver, kidney, brain, other)
Soft Tissue Repair 
(wounds, clotting)
Drug Delivery
Joint Repair/replacement
(hip, knee)
Bone Repair
(trauma, disease)
The Magic of Bioactive Glass
Powders Scaffolds Fibers Microspheres/beads
Bioactive glass reacts in the body and bonds strongly to hard and soft tissue
University of Missouri
Four Missions
• Teaching --- transfer of knowledge
• Research --- discovery of new 
knowledge
• Service --- helping others
• Economic development --- creating 
wealth from knowledge
A Case Study
Factors and events that were important to creating a 
successful business from life science technology that was 
spun off from university research--
MO-SCI Corp----founded in 1984, Rolla MO
Created to manufacture products for the health care 
industry---
glass microspheres for 
treating liver cancer     
TheraSphereTM
I- 70
I- 44
Courtesy of Mike NIchols
Factors important to the formation and  
early survival of MO-SCI Corp.
• State funded incubator program----shared 
facilities reduces start up expense
• University (MS&T)----receptive to aiding 
industry, fosters economic development by 
encouraging spin offs, labs & needed equipment 
available
• Available personnel & surroundings receptive to 
entrepreneurs
• Small Business Innovative Research (SBIR) 
program----important source of income
Profiles of Entrepreneurs in Incubators*
Personal traits
Location of business
Source of financing
Business Experience
Male, 35-40 yrs old, 17 yr of 
formal education
Near personal and family ties:
lived in area for 17 yr
>75% from personal funds,
mortgage, borrowed from 
friends & family; <25% from 
banks or venture capital
No formal training or
Marketing
Government assistance
experience; no written business 
plan 
Done by owner,“seat of pants”
analysis
Wary; too much paper work
* J.R. Mullin and J.H. Armstrong, “Profile: Prospective Tenants for Business Incubators,” Landuse, Inc. 
Hadley, Ma, 1987
INGREDIENTS FOR A SUCCESSFUL START UP
Supportive environment for entrepreneurs
Private Sector---Government---University
Everyone has a financial stake
Founders---University---Others
Plan for generating income
Dedication
hard work---long hours---luck
Being an entrepreneur can be a lot of fun
• A new company 
• 35 new jobs
• More than 950 customers in 40  
countries
• Direct economic benefit to MO 
>>> royalties paid to UM
>>> irradiation fees paid to UM
>>> new research dollars to MO
>>> new healthcare products   
produced in MOHealth care products made by MO-SCI   
--- TheraSphereTM
--- microspheres for blood typing           
--- glass fillers for dental composites    
--- bioactive glasses for bone repair      
--- antimicrobial glasses for catheters
Hdqs of MO-SCI Corp in Rolla MO
The Federal SBIR Program
• Established to help small businesses 
compete for government research funds               
• Federal agencies must set aside a part of 
their research budget for small business
• Agencies request proposals from small 
businesses---competitive awards  
• Phase I, 6 to 9 months, $60K to $100K
• Phase II, up to 2 yrs, $200K to $300K/yr
• Phase III,  commercialization
Provided a important source of income during 
initial start up (financially difficult period).
Enabled MO-SCI to perform important 
research/acquire equipment that otherwise 
couldn’t be afforded.
Benefits of SBIR Program to MO-SCI
Research performed under the SBIR Program 
has/is leading to new products.
Kept research an important business interest.
Small Business Innovation Research (SBIR) Awards in 
Missouri—1983-2002
Courtesy of Mike Nichols
Orthopedic Tissue 
Engineering
Michael Detamore, Ph.D.
Associate Professor of Chemical & Petroleum 
Engineering
University of Kansas
March 9, 2010

What does my group do?
• Tissue Engineering
• Biomaterials
• Stem Cells
Tissues of Interest
• Temporomandibular Joint
• Intervertebral Disc
• Knee (osteochondral)*
• Cranium*
• Trachea*
• Liver*
• Cochlea* *KUMC collaborator
Biomaterials Strategies
• Microsphere-
based gradient 
scaffolds
• Colloidal gels
• Electrospinning
• IPN hydrogels
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Biomaterials Strategies
• Microsphere-based 
gradient scaffolds
• Colloidal gels
• Electrospinning
• IPN hydrogels
Biomaterials Strategies
• Microsphere-
based gradient 
scaffolds
• Colloidal gels
• Electrospinning
• IPN hydrogels
Umbilical cord stromal 
cells
• Not cord blood, not HUVECs
• Combine with biomaterials
• Signaling strategies
• Comparisons to BMSCs
Collaborations & 
Commercialization
• Currently working with 
scientists, engineers, and 
surgeons
• Patents pending on gradient 
and IPN designs
• Interested in talking to 
entrepreneurs
Collaborations Across State 
Lines
• UMKC Dental School (bone biology)
• Children’s Mercy (ENT, orthopedics)
• Sinclair Research Center (in vivo)
• UM-Columbia (in vivo)
Questions?
Muscle Aging Sarcopenia is a FACT! 
What are we going to do about it?
Marco Brotto, B.S.N., M.S., Ph.D.
Associate Professor of Nursing, Medicine & Biological Sciences,
International Visiting Professor, Brazilian Council of Research 
Director,  Muscle Biology Group-MUBIG
University of Missouri-Kansas City
But, what is sarcopenia?
The power of an image
Beginning in the fourth decade of life, 
adults lose 3% to 5% of muscle mass 
per decade, a rate of decline that 
increases to 1% to 2% per year after the 
age 50 years.
Loss of skeletal muscle mass and 
strength is associated with declining 
health.
The cost of sarcopenia is in the 
hundreds of billions in the US and 
trillions in the world!
The devastating consequences of sarcopenia!
- 50%
Surprisingly, there is an almost universal lack of 
awareness of 
sarcopenia, its consequences, and working to delay it 
or 
reducing its effects.
What can we do about?
While these measure help, 
unfortunately they are still NOT enough
Our Innovative Research has Potential to Help
We have discovered that during 
aging disruption of intracellular 
calcium homeostasis develops, 
particularly compromised SOCE.
Using animal models of muscle 
research, we have discovered key genes 
(mg29, sarcalumenin, mg53, mip) that 
are important for muscle function. Some 
of these genes are down regulated 
during aging
MTMR14
Expression of MIP 
increased with muscle 
fiber formation and 
differentiation. MTMR14 is 
a phosphatidylinositol-3-
phosphatase that 
dephosphorylates 
PtdIns(3,5)P2, an 
essential second 
messenger! Mutations in 
MIP associated with 
muscle myopathies in 
humans
What else can we do?
The MIP-PI(3,5)P2 is a novel pathway that is essential for muscle development, for
and muscle function. Clinically relevant also. How about we partner to develop ne
to modulate this pathway? Gene therapy?
Following role models: Drs. Jianjie Ma and Noah Weisleder, MG53, and Trimedic
http://www.trim-edicine.com/About_Us.html
How about a blood diagnostic test for 
early detection of sarcopenia and aging 
frailty?
I really think that I have 
a great               for such a test! 
What else can we do?
The UMKC Muscle Biology Group recently discovered that hyperthermia induces 
hypertrophy in cardiac, smooth and skeletal muscle cells, alters calcium homeostasis, 
and activates a complex network of genes, including a pathway
We could partner to explore the healing effects of hyperthermia. 
New devices could be developed
Bones & Muscles talk to each other:
Muscle Biology Research Group & the Bone Biology Research Group
In collaboration with Dr. Leon-Salas, we are developing a new device for dual 
Electrical and electromagnetic stimulation of muscles and bones!
And you will see in Dr. Salas presentation, we already have some exciting data!
Muscles need activity:
Most of us are exercising less. Many can’t even exercise!
We are very thankful for
Support
• Missouri Life Sciences Research Board
• UMKC Center of Excellence of Mineralized Tissue
• National Institutes of Health
• American Heart Association
• Schools of Nursing, Medicine, Computer & Engineering, Dentistry
Outside Collaborators:
C-K Qu, Case Western Reserve University
Thomas Nosek, Case Western Reserve University
Hector Valdivia, University of Wisconsin
Jianjie Ma, Robert Wood Johnson Medical School
Hiroshi Takeshima, Tohuko University, Japan
University of Sciences & Technology, Salvador, Brazil
UMKC Collaborators
Lynda Bonewald
Mark Johnson
Walter Leon-Salas
MUBIG
NOT KNOWING IT WAS
IMPOSSIBLE,
WE COMPLETED THE MISSION!
Marco Brotto
Missouri Life Sciences Summit
March 8,9 2010
Daniel Leon-Salas
Assistant Professor
Computer Science Electrical Engineering 
Dept.
Outline
• Opportunities for collaborative work
• Case 3: Smart Stent
• Case 2:  Cell Stimulator
• Future Work
• Questions
We great expertise on
Integrated Circuits and Electronic Systems Design
CAD Software
Fabricated chip
Printed circuit board
Smart Stent
Sensor laden stent to assess the effects of in-stent restenosis
Microchip
Pressure sensors
Stent
Microchip
Stent
Solder 
bumps
Restenosis simply is the 
recurrence of stenosis, the 
narrowing of vessels.
It occurs in 25-30% of patients 
with stents
A smart stent could help 
reduce restenosis and health 
care costs
Electro-Magnetic Cell Stimulator
Why?
We know that electrical 
stimulation is good for 
muscles; clinically used to 
prevent muscle wasting.
We also know that 
electromagnetic stimulation is 
excellent for healing of bone 
fractures and prevention of 
bone wasting
Thus, we created the first
Dual stimulation device
And look at the effects in myoblasts
Control Dual Stimulation
This is very exciting because suggests that our device can enhance
Cell-cell communication, necessary for muscle repair/regeneration
We now want to move forward -Partners are welcomed
• We want to make a prototype to be tested 
in animals
• We want to make prototype to be tested in 
humans
• We predict that such a device if properly 
adapted for animals and humans could be 
highly beneficial in the treatment and 
prevention of muscle wasting and 
osteoporosis
Thank you
Time for Questions
